UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted
Lineage Cell Therapeutics buys NeuroAirmid and Huntington's program
Carlsbad, California-based Lineage Cell Therapeutics, a clinical-stage developer of off-the-shelf cell therapies, has acquired NeuroAirmid Therapeutics. The deal includes certain worldwide rights to hNSC-01, a pluripotent stem cell-derived neural cell therapy for Huntington's disease that Lineage calls HUNT1.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →